Infliximab in the surgical management of complex fistulating anal Crohn's disease

Talbot, Charlie; Sagar, P. M.; Johnston, Michael; Finan, P. J.; Burke, Dermot

doi:10.1111/j.1463-1318.2004.00749.x

Cited by 79 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antakia et al described 25% of reccurrence after total remission, and 45% in partial responders, in a median follow-up of 20 months (2) . Talbot et al described no recurrence in the 10 patients with total remission, with a similar follow-up period (20) . The durable maintenance of complete perianal remission with low recurrence rates in our study can be justified by the previous imaging tests in all patients, that helped to better identify secondary hidden fistula tracks.…”

Section: Discussionmentioning

confidence: 83%

“…We believe that this could be the best outcome to be identified in an observational retrospective case series. Talbot et al, classified the results after therapy in complete, partial or absent response (20) . Hyder et al, aimed a reduction in the Perianal Crohn's disease Activity Index (PDAI), a more objective measurement that was not used in our study due to its retrospective design (9) .…”

Section: Discussionmentioning

confidence: 99%

“…This number is similar to the rates found in the literature, in retrospective studies. Talbot et al described 47% of complete response to the treatment (20) , and Gaertner et al, in the subgroup that received IFX after seton placement, described aproximately 42% of complete healing, in 112 patients (8) . On the other hand, Antakia et al demonstrated a 29% rate of complete response and 42% of partial remission in a sample of 48 patients (2) .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study

Kotze

Albuquerque

Moreira

et al. 2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Perianal fistulizing Crohn's disease is one of the most severe phenotypes of inflammatory bowel diseases.Combined therapy with seton placement and anti-TNF therapy is the most common strategy for this condition. Objectives -The aim of this study was to analyze the rates of complete perianal remission after combined therapy for perianal fistulizing Crohn's disease. Methods -This was a retrospective observational study with perianal fistulizing Crohn's disease patients submitted to combined therapy from four inflammatory bowel diseases referral centers. We analyzed patients' demographic characteristics, Montreal classification, concomitant medication, classification of the fistulae, occurrence of perianal complete remission and recurrence after remission. Complete perianal remission was defined as absence of drainage from the fistulae associated with seton removal.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study

Kotze

Albuquerque

Moreira

et al. 2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Studies, which investigated the results of combined seton and anti-TNF treatment for PFCD, reported a great range of complete response rate between 18-75% (Table IV) [11,12,[15][16][17][18][19][20][21][22][23][24]. Table IV was meticulously prepared only for PFCD.…”

Section: Discussionmentioning

confidence: 99%

Seton drainage combined with anti-tnf therapy for perianal fistulizing Crohn’s disease, single center experience

Yardimci¹,

Kara²,

Attaallah³

et al. 2016

MMJ

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of combined treatment with anti-tumor necrosis factor (TNF) agents, and setons for perianal fistulas in Crohn's disease.Patients and Methods: Study included 27 consecutive patients with perianal fistulizing Crohn's disease, requiring seton drainage and anti-TNF therapy in our center from January 2013 to November 2014. All patients underwent a standardized pelvic magnetic resonance imaging (MRI) examination. Patient characteristics, follow up time, findings of pelvic MRI, colonoscopy and examination under anesthesia findings were recorded. Response to treatment was evaluated at the end of the follow up. Results:The median follow-up after treatment was 17 months (6-32). The fistula was complex in 24 (89%) of the 27 patients. Colonoscopy revealed ileitis in 16 (59.3%) patients and active proctitis in 9 (33.3%) patients. Perianal abscess was observed in 12 (44.4%) patients. Complete response was obtained in 17 (63%) patients. Only 3 (11.1%) patients experienced recurrence abscess during the study period. We could not find any factor, which were associated with complete response. Conclusion:Complete response was achieved in 63% of the patients, with perianal fistula formation associated with Crohn's disease, with combined seton drainage and anti-TNF therapy.

show abstract

“…All patients with high fistulas and one patient with a rectovaginal fistula had to be operated on several times to achieve complete healing. Regarding biological treatments introduced for treatment of CD in the late 1990s, compared with our study period, use of infliximab and adalilumab according present guidelines may reduce the need for surgical procedures such as in treating fistulas (27,28).…”

Section: Discussionmentioning

confidence: 99%

The Role of Surgery in Crohn's Disease: A Retrospective Analysis from a Single Hospital

2010

View full text Add to dashboard Cite

show abstract

Infliximab in the surgical management of complex fistulating anal Crohn's disease

Abstract: The combination of seton drainage and infusion of infliximab completely healed the perineum of 47% patients with complex fistulating perianal Crohn's disease. Partial response was seen in the remainder of patients. No serious adverse reactions reported.

Cited by 79 publications

References 34 publications

PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study

PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study

Seton drainage combined with anti-tnf therapy for perianal fistulizing Crohn’s disease, single center experience

The Role of Surgery in Crohn's Disease: A Retrospective Analysis from a Single Hospital

Contact Info

Product

Resources

About